Format

Send to

Choose Destination
Oncologist. 2011;16(10):1422-7. doi: 10.1634/theoncologist.2011-0137. Epub 2011 Sep 23.

Will imatinib compromise reproductive capacity?

Author information

1
UCSF Medical Center, Center for Reproductive Health, San Francisco, California, USA. RosenM@obgyn.ucsf.edu

Abstract

Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia-positive leukemias and selected other cancers, leading to a steady rise in the prevalence of patients using such therapy. Because failure of therapy would require conventional gonadotoxic chemotherapeutics, many female patients using imatinib may choose to preserve fertility. Herein, we provide evidence of a potential negative effect of imatinib on ovarian function by reporting the first case of a woman who showed a severely compromised ovarian response to gonadotropin stimulation while on imatinib, with a normal ovarian response after stopping this medication.

PMID:
21948652
PMCID:
PMC3228060
DOI:
10.1634/theoncologist.2011-0137
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center